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Background: The presence of depressive subsyndromal symptoms (SS) in bipolar disorder (BD) increases the risk of
affective relapse and worsens social, cognitive functioning, and quality of life. Nonetheless, there are limited data on
how to optimize the treatment of subthreshold depressive symptoms in BD. Mindfulness-Based Cognitive Therapy
(MBCT) is a psychotherapeutic intervention that has been shown effective in unipolar depression. The assessment of
its clinical effectiveness and its impact on biomarkers in bipolar disorder patients with subsyndromal depressive
symptoms and psychopharmacological treatment is needed.
Methods/design: A randomized, multicenter, prospective, versus active comparator, evaluator-blinded clinical trial
is proposed. Patients with BD and subclinical or mild depressive symptoms will be randomly allocated to: 1) MBCT
added to psychopharmacological treatment; 2) a brief structured group psychoeducational intervention added to
psychopharmacological treatment; 3) standard clinical management, including psychopharmacological treatment.
Assessments will be conducted at screening, baseline, post-intervention (8 weeks) and 4 month follow-up
post-intervention. The aim is to compare MBCT intervention versus a brief structured group psychoeducation.
Our hypothesis is that MBCT will be more effective in reducing the subsyndromal depressive symptoms and
will improve cognitive performance to a higher degree than the psychoeducational treatment. It is also hypothesized
that a significant increase of BDNF levels will be found after the MBCT intervention.
Discussion: This is the first randomized controlled trial to evaluate the effects of MBCT compared to an active control
group on depressive subthreshold depressive symptoms in patients with bipolar disorder.
Trial registration: ClinicalTrials.gov: NCT02133170. Registered 04/30/2014.
Keywords: Mindfulness, Psychoeducation, Bipolar disorder, Depression, Subsyndromal symptoms, Meditation, BDNF,
Randomized clinical trialBackground
Even in environments with standard psychiatric treat-
ment and regular follow-up, around 38% of patients who
have recovered from an acute episode of bipolar disorder
(BD) show persistent subthreshold symptoms (SS) [1].
The Depression Comorbidity Study shows that the time
with SS is higher than time in episode throughout the* Correspondence: consuelo.dios@salud.madrid.org
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unless otherwise stated.follow-up, with a clear predominance of depressive SS
[2]. In a Spanish cohort, patients were symptomatic for
one third of the 72-weeks follow-up, and also one third
of the visits. In addition, they spent three times more
days depressed than manic or hypomanic [3]. The per-
sistence of SS has been associated with an increased risk
of affective relapse/recurrence [4-6], a shorter time to
relapse [7], greater functional impairment − similar to
that experienced by patients with depressive episode−,Ltd. This is an Open Access article distributed under the terms of the Creative
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and poorer cognitive performance [10].
Nevertheless, few studies have assessed the efficacy of
treatments on bipolar patients with depressive SS. Evi-
dence of effectiveness using only drugs is limited, there-
fore alternatives are needed. Concomitant psychosocial
interventions are recommended, such cognitive behav-
ioral therapy (CBT), interpersonal and social rhythm
therapy (IPSRT) and structured psychoeducation, espe-
cially for stabilization between episodes and relapse pre-
vention [11]. In a recent study, a 21-session individual
CBT was shown as effective -but much less cost-effective-
as a brief psychoeducational group intervention, with
overall decrease in disease burden, effectiveness in pre-
venting episodes and time to relapse [12]. A combined
treatment (pharmacological plus psychoeducational and
cognitive-behavioral therapy) has shown to decrease de-
pressive symptoms, even in refractory BD, and the num-
ber of hospitalizations [13]. Despite psychoeducational
interventions appear to be most promising, the develop-
ment of effective psychosocial therapies is still needed.
Mindfulness and acceptance-based interventions (MABIs)
are receiving increasing attention in the treatment of mental
disorders and show promise for symptoms of anxiety and
depression both in clinical and nonclinical populations [14].
The practice of mindfulness works well in cognitive pro-
cesses (rumination, cognitive reactivity, experiential avoid-
ance), which have been associated with vulnerability to
depressive and anxious symptoms and neuropsychological
performance [15]. Mindfulness is currently defined in psy-
chological terms as “paying total attention to the present
moment with a non-judgmental awareness of inner and
outer experiences” [16]. The primary mechanism of action
is the moment-by-moment attention of our thoughts, feel-
ings, bodily sensations, and surrounding environment,
which promotes emotional regulation and awareness of
the basic processes influencing the attribution of meaning
to experiences. As important as the attention training is
the promotion of an attitude of openness, curiosity and
acceptance of all the experiences that arise. Mindfulness-
Based Cognitive Therapy (MBCT), developed by Segal,
Williams and Teasdale [17] is a group-based, 8-week,
mind-body intervention that integrates psychological edu-
cational aspects of CBT for depression with meditation
components of mindfulness-based stress reduction devel-
oped by Kabat-Zinn [16]). It has proven effective as adjunct-
ive therapy in preventing relapse of recurrent depressive
disorder [18-21] and reducing the residual depressive symp-
toms in unipolar depression [22,23]. In a pilot trial, MBCT
compared to psychoeducation was significantly more effect-
ive in improving subsyndromal depressive symptoms in pa-
tients with unipolar depression [24]. In addition, MBCT is
recommended in the NICE (National Institute for Health
and Clinical Excellence) clinical guideline for the treatmentof unipolar depressive patients with a history of 3 or more
episodes [25].
Some preliminary studies and a randomized controlled
trial with a long follow-up have examined MBCT in the
treatment for bipolar disorder. Williams et al. [26] con-
ducted a pilot clinical trial evaluating the effectiveness of
MBCT versus waitlist on between-episode anxiety and
depressive symptoms. Although the results were favor-
able for MBCT, these should be analyzed with caution
given the small size and heterogeneity of the sample.
Miklowitz et al. [27] studied the effect of a modified
MBCT protocol with two additional treatment elements
specifically designed for patients with bipolar disorder:
psychoeducation about mood changes and its provoking
factors (e.g. interpersonal conflict, sleep/wake cycle dis-
ruptions) and upon identification of these factors bring-
ing mindfulness to prodromal signs of mood elevation.
Small to medium effect sizes for improvement in depres-
sion and anxiety symptoms in remitted patients with bi-
polar disorder were found. In other preliminary study, at
the end of a MBCT treatment, as well as at the 3-month
follow-up, participants with BD showed lower residual
depressive mood symptoms, less attentional difficulties,
increased emotion-regulation abilities, psychological well-
being, more positive affect, and psychosocial functioning
and improvements in executive functioning, memory, and
ability to initiate and complete tasks [28]. Other controlled
studies have also shown a beneficial effect of MBCT for
patients with BD, but with limitations such as small sam-
ple, absence of randomization or of an active comparator
[29,30]. Perich et al. [31] have compared MBCT plus
treatment as usual (TAU) to TAU alone in a RCT over a
12 month follow-up period. MBCT did not lead to signifi-
cant reductions in time to depressive or hypo/manic
relapse, total number of episodes, or mood symptom
severity at 12-month follow-up; however, there was
some evidence for an effect on anxiety symptoms. Des-
pite decreases in depression were only observed at a
trend level, further research is required to analyze the
effect of MBCT on residual depressive symptoms in bi-
polar patients.
Mindfulness-based interventions are cost-effective, show-
ing a potential to significantly reduce societal costs and in-
crease the effectiveness of care [32]. Research in this field
has shown important methodological limitations: differ-
ences in the application of the MBCT intervention, both in
duration and number of sessions or the amount of incorpo-
rated psychoeducational elements; the limited statistical
power due to small sample size; lack of control for possible
confounding factors such as pharmacological treatment, or
lack of information on the severity of the disease; and scar-
city of long-term randomized clinical trials that allow to as-
sess the maintenance of achieved effects. In the present
project we try to overcome several of these limitations,
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with an active comparator, the larger sample size and the
attempt to control confounding variables regarding the
condition and design of the intervention.
Structured group psychoeducation is an adjunctive
psychological treatment that has been shown to be ef-
fective in the prevention of affective recurrences as well
as number of hospitalizations and time with symptoms
in BD euthymic outpatients, both at two-year [33] and
five-year follow-up [34]. This psychoeducational pro-
gram is structured in 21 sessions delivered through
6 months. It stresses the importance of illness aware-
ness, self-management, early-warning sign identification,
habit regularity, treatment adherence and avoiding drug
misuse. “It has been defined as “behavioural psychoedu-
cation”, but its authors rather think of it as an “attitudes
& aptitudes” psychoeducational program. This definitely
corresponded to a view of bipolar disorder as a complex
condition involving not only biological etiological factors
but also psychological and social variables that may act
as triggering factors, modulators or mediators” [35]. This
study has been successfully replicated in pharmacologic-
ally treated patients with bipolar disorder also in routine
clinical settings [36].
The brain -derived neurotrophic factor (BDNF) is a di-
meric protein that promotes the growth and maintenance
of neuronal connections, modulates neurotransmission
and participates in the mechanisms of learning and long-
term plasticity (LTP). Peripheral BDNF in serum and
plasma can be assessed noninvasively by venipuncture.
Since it crosses the blood–brain barrier, its levels in serum
and plasma are highly correlated with levels in cerebro-
spinal fluid (r ¼ 0.8) [37,38]. There are numerous studies
assessing peripheral levels of BDNF in bipolar disorder pa-
tients. Some studies suggest that BDNF levels decrease
during mood acute states and remain normal during
euthymia, but other studies have contradicted this para-
digm. A recent meta-analysis has measured the effect sizes
of the differences in BDNF levels between BD patients in
different mood states and controls. The BDNF levels were
decreased in both mania and depression when compared
to controls [39,40] but were not different in euthymia
[41]. Meta-regression analyses in euthymia showed that
age and length of illness influenced the variation in ef-
fect sizes [42]). BDNF levels are consistently reduced
during manic and depressive episodes and recover
after treatment for acute mania, so peripheral BDNF
could be used as a biomarker of mood states and dis-
ease progression for BD.
In summary, the presence of persistent depressive sub-
threshold symptoms increases the risk of affective relapse
and negatively affects the prognosis of BD. However, there
is no an evidence-based specific treatment for them.
MBCT appears as a promising intervention, since it hasbeen found to be effective in reducing current depressive
symptoms in MDD [23,43]. Our objective is to evaluate
the efficacy of the MBCT added to standard drug treat-
ment -following the recommendations of the Spanish
Guideline for the Treatment of BD [11])- versus structured
group psychoeducation versus standard clinical manage-
ment. Our primary outcome is reduction of residual de-
pressive symptoms. Secondary outcomes are manic and
anxiety symptoms, recurrence, cognitive and social func-
tioning and levels of BDNF.
Methods/design
This is a parallel 3-group, multicenter, prospective, ran-
domized; single-blind (evaluator) controlled pilot trial,
with a 4 month follow-up post-intervention. Patients
diagnosed with bipolar disorder (BD) according to
DSM −5 criteria for mild depression or subsyndromal
depressive symptoms are assigned to one of the fol-
lowing 3 treatment groups: 1) psychopharmacological
treatment plus Mindfulness Based Cognitive Therapy
(MBCT); 2) psychopharmacological treatment plus a
brief, structured group psychoeducation; 3) treatment
as usual (TAU), defined as standard psychiatric care
with standard pharmacologic treatment. After written
informed consent is signed, patients meeting the in-
clusion criteria are randomized (2:2:1 ratio) through a
Random Allocation Software. All three groups are
assessed at baseline (t0), immediately after complet-
ing the program (t1; 8 weeks) and at follow-up six
months after randomization. The assessments include
the following variables: depression, manic and anxiety
symptoms, general and social cognition, global functioning,
BDNF, and other clinical variables. The evaluator who will
collect the biomarkers and the clinical and psychometric
data will be blind to allocation of treatment. The interrater
variability between all researchers will be checked.
Subjects
One hundred and forty bipolar out-patients with per-
sistent mild/subsyndromal depressive symptoms will
be recruited from Mental Health Centers as well as
Private Psychiatric Clinics and Bipolar Patient Associa-
tions via announcements or physician referral. The
study will be conducted in La Paz University Hospital
(Madrid) and the Santiago Apóstol University Hospital
(Vitoria).
Inclusion criteria
1-Age: 18–60 years; 2 – BD type I or II, in clinical re-
mission of acute mood episode at least in the three
months prior to study; 3 - Having experienced an acute
affective episode in the past 3 years, 4 - Having suffered
at least two lifetime depressive episodes. 5- Monother-
apy or combination with a mood stabilizer (lithium,
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(i.e., in serum levels within the therapeutic range: 0.6-
1.2 mEq/L for lithium, 50–100 ug/mL for valproate, and
5–12 mcg/mL for carbamazepine), or quetiapine mono-
therapy or in combination with the aforementioned stabi-
lizers, or any oral atypical antipsychotic in combination
with an antidepressant; 6.- Hamilton Depression Rating
Scale [HDRS]–17 [44] score ≥ 8 and ≤ 19 and Young Mania
Rating Scale [YMRS; 49] score <8; 7 - Being able to under-
stand and comply with the requirements of the trial, 8 -
Written consent to participate in the study.
Exclusion criteria
1. Any acute mood episode in the 12 weeks before the
start of the trial. 2. Any current DSM −5 diagnosis dif-
ferent from bipolar disorder (including substance or al-
cohol use disorder at the time of study entry, except if it
is under complete remission. Not applicable to nicotine
or caffeine). 3. Risk of suicide or self/hetero aggressive-
ness. 4. Pregnancy. 5. Severe and unstable medical dis-
ease. 6. Patients who are currently receiving structured
psychotherapy or structured group psychoeducation
about bipolar disorder, or who have received struc-
tured psychoeducation in the past 5 years; 6. Patients
who are treated with a different mood stabilizer than lith-
ium, valproate, carbamazepine, lamotrigine, a classic anti-
psychotic or antidepressant monotherapy at the time of the
randomization. 7. Treatment with a depot antipsychotic;
8. Participation in another clinical trial within 4 weeks
prior to randomization. 9. Mental retardation.
Withdrawal criteria
Express wish of the participant, unjustified absence from
more than two group training sessions, appearance of
suicidal ideation or psychotic symptoms, onset of acute
manic or hypomanic episode, or need for psychiatric
hospitalization from any cause.
Primary outcome measures
Primary endpoint of the study is given by changes in the
overall score of the Hamilton Rating Scale for Depres-
sion (HDRS [44]), from baseline (V0) to week 8 (v1) for
each of the treatment groups.
Secondary endpoints
1. Changes in the global score of Young Mania Rating
Scale (YMRS, [45]) from baseline (V0) to visit 1 (at
the end of the 8 week intervention (v1)
2. Changes in the score of Clinical Global Impression
CGI-BP [46] from baseline (V0) to visit 1;
3. Changes in the score of the Hamilton Rating Scale
for Anxiety HAM-A [47] from baseline (V0) to
visit 1;4. Cognitive changes: changes at the end of the
intervention will be assessed with the following
measures:
– sustained and selective attention
– working memory and executive functions
– perception of the attitude of mindfulness (Five
Facet Mindfulness Questionnaire FFMQ, [48]) in
patients in the experimental group
– scales of social cognition
5. Functioning: changes in total scale score of the
Functioning Assessment Short Test (FAST; [49]).
6. The following clinical variables are also assessed:
– Recurrence, defined as the emergence of a new
acute episode whether depressive, mixed, hypo or
manic at any time throughout the study,
according to DSM-5 clinical criteria or when the
score on the HDRS scale is ≥ 20 (depressive epi-
sode) or the Young scale ( YMRS ≥ 8) (hypo/
manic episode), or a change drug or
hospitalization is needed.
– Plasma levels of BDNF: changes from baseline to
visit 1 (end of intervention).
Twenty-four weeks after the start of intervention fol-
lowing measurements are assessed: changes in the
overall score of the Hamilton Depression Rating Scale
(HDRS [44]), Young Mania Rating Scale (YMRS, [45])
from baseline (V0 ) to week 24 (V2) , Hamilton anxiety
Scale HAM- A [47], CGI [46], general cognitive func-
tioning, social cognition, functioning and biomarkers
(BDNF).
Intervention
MBCT program will be conducted in HULP by two
experienced therapists with recognized expertise in
Mindfulness based stress reduction (MBSR), MBCT
and narrative psychotherapy. Both therapists will train
two therapists from Vitoria with expertise in cognitive
therapy and MBSR. The MBCT program consists of 8
weekly sessions of 90 minutes and will be performed in
groups of approximately 10–15 patients. All therapy ses-
sions will be audio recorded to be discussed and analyzed
by the treatment team, in order to standardize the inter-
vention. Treatment fidelity will be also assessed using the
Mindfulness- based Cognitive Therapy Adherence Scale
(MBCT-AS; [50]), which assesses the key constructs of
MBCT during group sessions.
Psychoeducation program will be held in groups of 10
to 15 patients in 90-minute weekly sessions led by two
therapists blind to the clinical and cognitive evaluation.
The specific program of 8 sessions addresses disease
awareness, adherence to treatment and early detection of
prodromal symptoms. Homework will also be included.
The program is based on the Psychoeducation Manual for
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1 Depressive symptoms: measured by the Hamilton De-
pression Rating Scale of 17 items (HDRS-17) [44,52]. 3.
Manic symptoms: measured by the Young Mania Rating
Scale (YMRS) [45]. 4. Hamilton Anxiety Scale HAM-A
[47]. 5. Clinical Global Impression Scale modified for bi-
polar disorder (CGI-BP) [46]. 6. Adherence to treatment:
Good (according to information from the patient, family and
blood drug levels), Bad (if none of the above criteria are met)
or Average (only if it meets one or two criteria). 7. Clinical
outcome: new mood episodes, serious adverse events (in-
cluding suicidal ideation, suicide and hospitalization).
b) Cognitive variables
General cognition
– Sustained attention (Continuous Performance Test,
[53]). The test provides the following measures:
correct responses, errors of omission (not
responding when the stimulus appears) and
commission errors (responding without the letter
stimulus appearance).
– Selective attention (Stroop Test, [48]). Requires the
subject to be able to suppress irrelevant response.
When the name of a color (e.g., “blue,” “green,” or
“red”) is printed in a color not denoted by the name
(e.g., the word “red” printed in blue ink instead of
red ink), naming the color of the word takes longer
and is more prone to errors than when the color of
the ink matches the name of the color [54].
– Working memory. 1. Subtest from the Weschler
Adult Intelligence Scale [55]. A sequence from 2 to
8 digits or a list of words have to be repeated in
reverse or random order of presentation.
– Executive functions: 1. Wisconsin Card Sorting Task
[56]. Participants have to sort the cards according to
different criteria that vary throughout the test
(perseverative errors and completed categories are
the dependent variables).
c) Social cognition
The recognition of emotions through the face is mea-
sured with the Face Emotion Identification Task and
Face Emotion Discrimination Task (FEIT and FEDT re-
spectively, [57]). The FET scale includes 19 photographs
of faces expressing one of the six basic emotions (happy,
sad, angry, scared, shocked or embarrassed). The task is
to identify the patient’s emotion expressed in each. The
FEDT includes 30 pairs of faces and the subject mustdetermine if both sides show the same or different
emotion.d) Mindfulness
Five Factors Questionnaire Mindfulness (FFMQ, [58]) 39
items assessing five mindfulness facets: observing, de-
scribing, acting with awareness, equanimity and no re-
activity. Each item is scored on a Likert scale ranging from
1 (never) to 5 (very often). A high internal consistency and
high predictive validity have been shown [58] and it has
been uvalidated in Spanish [59].e) Functioning
Measured with the Functioning Assessment Short Test
(FAST, [49]), which measures the degree of difficulty
found by the patient in the following areas: autonomy,
occupational functioning, cognitive functioning, finances,
relationships and leisure.f) Biomarkers: serum analysis of BDNF
Data analysis
An exploratory study of all collected variables identifies
possible outliers and errors. The descriptive analyses of
qualitative variables are expressed as frequencies and
percentages and quantitative variables as mean, standard
deviation, median and interquartile range. Analysis is
performed by intention to treat. Comparison of qualita-
tive variables between the intervention groups or be-
tween other factors of segmentation is by means of Chi
2 or Fisher ‘s exact test. For quantitative variables, the T-
test, Mann -Whitney or Kruskal –Wallis and ANOVA
are applied, depending on the normality of the variable
(tested by Kolmogorov -Smirnov - Lilliefords). The change
analyses along the track of the primary and secondary out-
come variables are performed using a General Linear
Model (ANOVA with repeated measures). Regression
models are extracted to identify prognostic factors for the
efficacy variables. The statistical package SPSS 18.0 is used
in all tests and a bilateral level of p < 0.05 is considered sta-
tistically significant.Ethical issues
The study is conducted according to local regulations
and internationally established principles at the the
Helsinki Statement (64° Asamblea General Fortaleza,
Brasil, 2013), whilst respecting confidentiality (Data
Protection Act 15/99). Protocol was approved by the
Clinical Research Ethics Committee of the University
Hospital La Paz (Madrid) and the Clinical Research
Ethics Committee of the Basque Country.
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This study will provide feasibility information and pre-
liminary effect size estimates to inform the effectiveness
of adjunctive MBCT, adjunctive group psychoeducation
and standard treatment on SS or mild depressive symp-
toms in BD. It is of interest to researchers involved in
the development of new approaches to the treatment of
residual affective symptoms and its negative impact in
the course of illness. It can also provide information on
variations of BDNF in the different treatment arms and on
neuropsychological measures, which might suggest mech-
anisms of action and differences among treatments.
Strengths of the study include targeting a defined sam-
ple of bipolar patients with persistent depressive symptoms
despite receiving a correct pharmacological treatment. This
sample –as reported before- is representative of a high per-
centage of bipolar out-patients, who remain symptomatic
more than one third of the time. The trial protocol was
registered before randomization began (ClinicalTrials.gov:
NCT02133170 Registered 04/30/2014) and was developed
according to good clinical research practice enabling the
randomized trial to be conducted with low risk of bias and
a high degree of external validity. Both MBCT and psy-
choeducational interventions will be conducted using man-
uals and adherence to the treatment manuals will be
tested. This makes it possible to implement the interven-
tions in clinical practice, and the two interventions can be
assessed in future trials. To standardize the application of
MBCT and psychoeducation, specific training and meet-
ings will be held. Specific training also may increase the
inter-rater reliability on scales.
Since an 8-week psychoeducational program based in
the Barcelona group-structured model has not proved
effective neither in depressive symptoms nor in episode
prevention, this could be a study weakness. But our ob-
jective is to compare MBCT versus an active psycho-
social intervention, and this is the best model we could
find. Sample size could also be a limitation, as well as
the time of follow-up, especially regarding the possible
effects on long-term course of BD.
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